Neuro-Oncology AdvancesMolecular BiologyPeer-reviewed journal article
Aggressive high-grade NF2 mutant meningiomas downregulate oncogenic YAP signaling via the upregulation of VGLL4 and FAT3/4.
Abigail G ParrishiD, Sonali AroraiD, H. Nayanga ThirimanneiD, Dmytro RudoyiD, Sebastian Schmid, Philipp SieversiD, Felix SahmiD, Eric C. HollandiD, Frank SzulzewskyiD
Abstract
Meningiomas are the most common primary brain tumors in adults. Although generally benign, a subset of meningiomas is of higher grade, shows aggressive growth behavior and recurs even after multiple surgeries. Around half of all meningiomas harbor inactivating mutations in NF2. While benign low-grade NF2 mutant meningiomas exhibit few genetic events in addition to NF2 inactivation, aggressive high-grade NF2 mutant meningiomas frequently harbor a highly aberrant genome. We and others have previously shown that NF2 inactivation leads to YAP1 activation and that YAP1 acts as the pivotal oncogenic driver in benign NF2 mutant meningiomas. Using bulk and single-cell RNA-Seq data from a large cohort of human meningiomas, we show that aggressive NF2 mutant meningiomas harbor decreased levels YAP1 activity compared to their benign counterparts. Decreased expression levels of YAP target genes are significantly associated with an increased risk of recurrence. We then identify the increased expression of the YAP1 competitor VGLL4 as well as the YAP1 upstream regulators FAT3/4 as a potential mechanism for the downregulation of YAP activity in aggressive NF2 mutant meningiomas. High expression of these genes is significantly associated with an increased risk of recurrence. In vitro, overexpression of VGLL4 resulted in the downregulation of YAP activity in benign NF2 mutant meningioma cells, confirming the direct link between VGLL4 expression and decreased levels of YAP activity observed in aggressive NF2 mutant meningiomas. Our results shed new insight on the biology of benign and aggressive NF2 mutant meningiomas and may have important implications for the efficacy of therapies targeting oncogenic YAP1 activity in NF2 mutant meningiomas.
- organism: human
- assay: bulk RNA-seq
- assay: scRNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
- Citations
- 6
- FWCI
- 1.35
- Field percentile
- top 23%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2-mutant meningiomas in mice
F. Szulzewsky, S. Arora, … E. C. Holland·bioRxiv·May 2, 2022
- YAP-TEAD-driven CPA4 promotes NF2-deficient meningioma growth
Kentaro Mineji, Katerina Petrosky, … Rintaro Hashizume·bioRxiv·Aug 7, 2026
- PTEN deficiency linked to chromosome 10q loss leads to aggressive NF2mutant meningioma biology
Abigail G Parrish, H. Nayanga Thirimanne, … Eric C. Holland·bioRxiv·Dec 22, 2025
- Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant lines.
Dylan J Keiser, Meghan S Buddy, … Frank Szulzewsky·bioRxiv·Mar 25, 2026
- NF2 Loss-of-Function and Hypoxia Drive Radiation Resistance in Grade 2 Meningiomas
Bhuvic Patel, Sangami Pugazenthi, … Albert H. Kim·JNCI Journal of the National Cancer InstitutePeer-reviewed·Jan 27, 2025
- Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors
A. J. Patel, Y.-W. Wan, … T. J. Klisch·bioRxiv·Sep 10, 2019